AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 91 min read

BioLife Solutions director disposes of 57,995 shares

BioLife Solutions director Rachel Ellingson sold 57,995 shares on October 6, 2026, as part of a merger with Repligen. Each share was converted to $11.25 in cash and 0.1442 Repligen shares, per the merger agreement. Ellingson held no shares post-transaction.

Original reporting
stocktitan.net
Published Oct 9, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$BLFS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Why it matters

The insider sale is a routine post‑merger transaction with limited market impact.

02

Market read

Small insider sale after merger; unlikely to move the stock significantly.

03

What to watch

Potential tax or liquidity reasons for the sale that do not reflect company fundamentals.

Relevance 4/10Novelty 4/10Timing: post‑merger disclosure on Oct 6 2026

Background

BioLife Solutions completed its merger with Repligen, converting each share into cash and Repligen stock. The filing reports the director's share disposition.

Market effects

Sector

Minimal; the biotech merger has already been priced in.

Regional

None; the filing is company‑specific.

Global

None

Counterpoint

What could challenge this read

The insider sale could be interpreted as a lack of confidence in post‑merger integration.

Key entities

  • company
    BioLife Solutions Inc.

    Biotech firm completing merger with Repligen.

  • person
    Rachel Ellingson

    Director of BioLife Solutions who sold her shares.

Read at source← All news

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$RGENHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min
SEP 4
$RGENMedAI 8/10

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement

BioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.

stocktitan.net2 min